文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Software-Tool Support for Collaborative, Virtual, Multi-Site Molecular Tumor Boards.

作者信息

Schapranow Matthieu-P, Borchert Florian, Bougatf Nina, Hund Hauke, Eils Roland

机构信息

Hasso Plattner Institute for Digital Engineering, University of Potsdam, Prof.-Dr.-Helmert-Str. 2-3, 14482 Potsdam, Germany.

Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg University Hospital, Im Neuenheimer Feld 450, 69120 Heidelberg, Germany.

出版信息

SN Comput Sci. 2023;4(4):358. doi: 10.1007/s42979-023-01771-8. Epub 2023 Apr 27.


DOI:10.1007/s42979-023-01771-8
PMID:37131499
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10136394/
Abstract

The availability of high-throughput molecular diagnostics builds the foundation for Molecular Tumor Boards (MTBs). Although more fine-grained data is expected to support decision making of oncologists, assessment of data is complex and time-consuming slowing down the implementation of MTBs, e.g., due to retrieval of the latest medical publications, assessment of clinical evidence, or linkage to the latest clinical guidelines. We share our findings from analysis of existing tumor board processes and defininion of clinical processes for the adoption of MTBs. Building on our findings, we have developed a real-world software prototype together with oncologists and medical professionals, which supports the preparation and conduct of MTBs and enables collaboration between medical experts by sharing medical knowledge even across the hospital locations. We worked in interdisciplinary teams of clinicians, oncologists, medical experts, medical informaticians, and software engineers using design thinking methodology. With their input, we identified challenges and limitations of the current MTB approaches, derived clinical process models using Business Process and Modeling Notation (BMPN), and defined personas, functional and non-functional requirements for software tool support. Based on it, we developed software prototypes and evaluated them with clinical experts from major university hospitals across Germany. We extended the Kanban methodology enabling holistic tracking of patient cases from "backlog" to "follow-up" in our app. The feedback from interviewed medical professionals showed that our clinical process models and software prototype provide suitable process support for the preparation and conduction of molecular tumor boards. The combination of oncology knowledge across hospitals and the documentation of treatment decision can be used to form a unique medical knowledge base by oncologists for oncologists. Due to the high heterogeneity of tumor diseases and the spread of the latest medical knowledge, a cooperative decision-making process including insights from similar patient cases was considered as a very valuable feature. The ability to transform prepared case data into a screen presentation was recognized as an essential feature speeding up the preparation process. Oncologists require special software tool support to incorporate and assess molecular data for the decision-making process. In particular, the need for linkage to the latest medical knowledge, clinical evidence, and collaborative tools to discuss individual cases were named to be of importance. With the experiences from the COVID-19 pandemic, the acceptance of online tools and collaborative working is expected to grow. Our virtual multi-site approach proved to allow a collaborative decision-making process for the first time, which we consider to have a positive impact on the overall treatment quality.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/465938fd4c65/42979_2023_1771_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/4ce0e98769fc/42979_2023_1771_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/56ca0052214d/42979_2023_1771_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/a35ff1c19ddd/42979_2023_1771_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/4f07ed36b5e2/42979_2023_1771_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/3faa9a4e59ea/42979_2023_1771_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/e031861912d3/42979_2023_1771_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/f063f8603b1d/42979_2023_1771_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/f6394b6d2550/42979_2023_1771_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/465938fd4c65/42979_2023_1771_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/4ce0e98769fc/42979_2023_1771_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/56ca0052214d/42979_2023_1771_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/a35ff1c19ddd/42979_2023_1771_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/4f07ed36b5e2/42979_2023_1771_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/3faa9a4e59ea/42979_2023_1771_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/e031861912d3/42979_2023_1771_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/f063f8603b1d/42979_2023_1771_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/f6394b6d2550/42979_2023_1771_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f2/10136394/465938fd4c65/42979_2023_1771_Fig9_HTML.jpg

相似文献

[1]
Software-Tool Support for Collaborative, Virtual, Multi-Site Molecular Tumor Boards.

SN Comput Sci. 2023

[2]
The future of Cochrane Neonatal.

Early Hum Dev. 2020-11

[3]
Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.

Oncologist. 2021-8

[4]
The value of virtual molecular tumor boards for informed clinical decision-making.

Oncologist. 2024-7-5

[5]
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

Cochrane Database Syst Rev. 2022-2-1

[6]
The Role of Artificial Intelligence on Tumor Boards: Perspectives from Surgeons, Medical Oncologists and Radiation Oncologists.

Curr Oncol. 2024-8-27

[7]
Data-driven support to decision-making in molecular tumour boards for lymphoma: A design science approach.

Front Oncol. 2022-11-15

[8]
AMBAR - Interactive Alteration annotations for molecular tumor boards.

Comput Methods Programs Biomed. 2023-10

[9]
Sharing clinical decisions for multimorbidity case management using social network and open-source tools.

J Biomed Inform. 2013-6-25

[10]
Critical Care Network in the State of Qatar.

Qatar Med J. 2019-11-7

引用本文的文献

[1]
The Role of Algorithms in Molecular Tumour Boards-Managing the Gap Between Research and Clinic in Precision Medicine.

Sociol Health Illn. 2025-5

[2]
The Use of an Integrated Digital Tool to Improve the Efficiency of Multidisciplinary Tumor Boards-A Prospective Trial in Taiwan.

Cancers (Basel). 2025-1-28

[3]
Empowering personalized oncology: evolution of digital support and visualization tools for molecular tumor boards.

BMC Med Inform Decis Mak. 2025-1-16

[4]
Empowering precision medicine: regenerative AI in breast cancer.

Front Oncol. 2024-9-20

[5]
Data Visualization Support for Tumor Boards and Clinical Oncology: Protocol for a Scoping Review.

JMIR Res Protoc. 2024-3-5

[6]
Extending cBioPortal for Therapy Recommendation Documentation in Molecular Tumor Boards: Development and Usability Study.

JMIR Med Inform. 2023-12-11

本文引用的文献

[1]
Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation.

J Oncol Pharm Pract. 2023-7

[2]
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

Nat Cancer. 2022-2

[3]
Comparison of Treatment Recommendations by Molecular Tumor Boards Worldwide.

JCO Precis Oncol. 2018-11

[4]
An annotated dataset for extracting gene-melanoma relations from scientific literature.

J Biomed Semantics. 2022-1-19

[5]
Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine.

Genes Chromosomes Cancer. 2022-6

[6]
Knowledge bases and software support for variant interpretation in precision oncology.

Brief Bioinform. 2021-11-5

[7]
Strengths and limitations of video-conference multidisciplinary management of breast disease during the COVID-19 pandemic.

Br J Surg. 2021-1-27

[8]
Virtual oncology clinics during the COVID-19 pandemic.

Ir J Med Sci. 2021-11

[9]
Mastermind: A Comprehensive Genomic Association Search Engine for Empirical Evidence Curation and Genetic Variant Interpretation.

Front Genet. 2020-11-13

[10]
Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience.

JCO Precis Oncol. 2018-8-16

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索